[1] [1] BRUNEAU J, MOLINA T J. Hematopathology encyclopedia of pathology[M]. Berlin: Springer, 2020.

[2] [2] KLANOVA M, KLENER P. BCL-2 proteins in pathogenesis and therapy of B-cell non-Hodgkin lymphomas[J]. Cancers (Basel), 2020, 12(4): 938.

[3] [3] KIM S, NAM S J, KWON D, et al. MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system[J]. BMC Cancer, 2016, 16: 363.

[4] [4] HATZL S, POSCH F, DEUTSCH A, et al. Immunohistochemistry for c-myc and Bcl-2 overexpression improves risk stratification in primary central nervous system lymphoma[J]. Hematol Oncol, 2020, 38(3): 277-283.

[5] [5] OZTURK K, SOYLU E, CAYCI Z. Differentiation between primary CNS lymphoma and atypical glioblastoma according to major genomic alterations using diffusion and susceptibility-weighted MR imaging[J]. Eur J Radiol, 2021, 141: 109784.

[7] [7] GARABA A, ASLAM N, PONZIO F, et al. Radiomics for differentiation of gliomas from primary central nervous system lymphomas: a systematic review and meta-analysis[J]. Front Oncol, 2024, 14: 1291861.

[9] [9] LIU G L, ZHANG X Y, ZHANG N, et al. Detecting double expression status in primary central nervous system lymphoma using multiparametric MRI based machine learning[J]. J Magn Reson Imaging, 2024, 59(1): 231-239.